Novartis hits another setback in plan to repurpose rare disease drug in lung cancer

Novartis' plans to repurpose a rare disease drug as a lung cancer treatment have yet to bear fruit, with the Swiss drugmaker reporting Monday that the therapy failed to meet its goal in a second Phase 3 study.